Core Viewpoint - The company Codex-B (02487.HK) announced positive topline results from its Phase III clinical trial for CU-20101 (injectable type A botulinum toxin) aimed at improving moderate to severe glabellar lines in China [1] Group 1: Clinical Trial Details - The clinical trial is a two-phase study, with the first phase being a randomized, multi-center, double-blind, positive drug-controlled trial [1] - The second phase is an open-label clinical trial designed to evaluate the efficacy and safety of CU-20101 [1] - The trial uses the reference product Botox® (injectable type A botulinum toxin) as a control [1] Group 2: Timeline - The clinical trial is expected to complete enrollment of all subjects by November 2025 [1] - Database lock is anticipated to be completed in early January 2026 [1]
科笛-B(02487.HK)：CU-20101(注射用A型肉毒毒素)用于改善中度至重度眉间纹的中国III期临床试验取得积极的顶线结果